| Name | Nuformix |
|---|---|
| Epic | NFX |
| Isin | GB00BYW79Y38 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.33p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £6.86 | Debt ratio | n/a |
| Shares in issue | 1,995.71 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 1862.26 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.46 | 52-week high / low | 0.05p / 0.49p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Nuformix |
|---|---|
| Address | C/O Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, United Kingdom, EC2N 4BQ |
| Telephone | +44 (0)1223 627222 |
| Website | https://nuformix.com/ |
| Director | Position |
|---|---|
| Dr Daniel Gooding | Executive Director |
| Mr Julian Gilbert | Non-Executive Chairman |
| Mrs Madeleine Kennedy | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/09/24 | 30/09/23 | 31/03/22 |
| Intangible asssets and goodwill | 0.91 | 4.08 | 4.15 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.91 | 4.08 | 4.15 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.03 | 0.07 | 0.2 |
| Cash and equivalents | 0.02 | 0.2 | 0.46 |
| Other current assets and asset held for resale | n/a | 0.07 | 0.16 |
| Total of all assets | 0.97 | 4.42 | 4.98 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.25 | 0.22 | 0.24 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.25 | 0.22 | 0.24 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 0.72 | 4.2 | 4.74 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.82 | 0.74 | 0.62 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -9.84 | -6.21 | -7.35 |
| Share premium account | 6.73 | 6.66 | 6.5 |
| Total equity | 0.72 | 4.2 | 4.74 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -3.65 | -0.93 | -1.27 |
| Pre-tax profit | -3.65 | -0.93 | -1.27 |